vipor: a multi-targeted therapy for the treatment of r/r dlbcl
Published 6 months ago • 142 plays • Length 2:15Download video MP4
Download video MP3
Similar videos
-
2:35
association of interim pet2 response with outcomes in patients with dlbcl
-
1:28
how the standard of care for dlbcl is changing with the introduction of novel agents
-
0:42
targeted therapies for dlbcl treatment
-
0:57
immunotherapeutic approaches for mcl patients who progress following btki treatment
-
2:52
can we offer a curative treatment to transplant-ineligible r/r dlbcl patients?
-
0:44
clinical efficacy and safety of ct-p10 in patients with dlbcl
-
1:54
the important role of bispecific antibodies in the future treatment of r/r dlbcl
-
1:53
the current immunotherapeutic landscape for treatment of dlbcl
-
2:48
btk inhibitors in the treatment of dlbcl: trials investigating these agents
-
2:44
data on new therapeutic strategies in hodgkin lymphoma
-
2:08
cellular and targeted therapies for hodgkin lymphoma
-
1:22
diagnostics and treatment outcomes from primary cbcl
-
0:32
patient selection for ctcl
-
1:54
the potential role of cellular therapies and vaccines in the future treatment of mpns
-
3:05
the benefits of pet in the prognosis and treatment of hl
-
3:02
new technologies informing soc in dlbcl
-
3:06
results of trial on the use of interim pet scan to identify dlbcl